Literature DB >> 32040319

The Metabolic Rainbow: Deep Learning Phase I Metabolism in Five Colors.

Na Le Dang1, Matthew K Matlock1, Tyler B Hughes1, S Joshua Swamidass1.   

Abstract

Metabolism of drugs affects their absorption, distribution, efficacy, excretion, and toxicity profiles. Metabolism is routinely assessed experimentally using recombinant enzymes, human liver microsome, and animal models. Unfortunately, these experiments are expensive, time-consuming, and often extrapolate poorly to humans because they fail to capture the full breadth of metabolic reactions observed in vivo. As a result, metabolic pathways leading to the formation of toxic metabolites are often missed during drug development, giving rise to costly failures. To address some of these limitations, computational metabolism models can rapidly and cost-effectively predict sites of metabolism-the atoms or bonds which undergo enzymatic modifications-on thousands of drug candidates, thereby improving the likelihood of discovering metabolic transformations forming toxic metabolites. However, current computational metabolism models are often unable to predict the specific metabolites formed by metabolism at certain sites. Identification of reaction type is a key step toward metabolite prediction. Phase I enzymes, which are responsible for the metabolism of more than 90% of FDA approved drugs, catalyze highly diverse types of reactions and produce metabolites with substantial structural variability. Without knowledge of potential metabolite structures, medicinal chemists cannot differentiate harmful metabolic transformations from beneficial ones. To address this shortcoming, we propose a system for simultaneously labeling sites of metabolism and reaction types, by classifying them into five key reaction classes: stable and unstable oxidations, dehydrogenation, hydrolysis, and reduction. These classes unambiguously identify 21 types of phase I reactions, which cover 92.3% of known reactions in our database. We used this labeling system to train a neural network model of phase I metabolism on a literature-derived data set encompassing 20 736 human phase I metabolic reactions. Our model, Rainbow XenoSite, was able to identify reaction-type specific sites of metabolism with a cross-validated accuracy of 97.1% area under the receiver operator curve. Rainbow XenoSite with five-color and combined output is available for use free and online through our secure server at http://swami.wustl.edu/xenosite/p/phase1_rainbow.

Entities:  

Mesh:

Year:  2020        PMID: 32040319      PMCID: PMC8716320          DOI: 10.1021/acs.jcim.9b00836

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  78 in total

1.  Antibacterial and antifungal polyine compounds from Glehnia littoralis ssp. leiocarpa.

Authors:  H Matsuura; G Saxena; S W Farmer; R E Hancock; G H Towers
Journal:  Planta Med       Date:  1996-06       Impact factor: 3.352

2.  SMARTCyp: A 2D Method for Prediction of Cytochrome P450-Mediated Drug Metabolism.

Authors:  Patrik Rydberg; David E Gloriam; Jed Zaretzki; Curt Breneman; Lars Olsen
Journal:  ACS Med Chem Lett       Date:  2010-03-15       Impact factor: 4.345

Review 3.  Applying mechanisms of chemical toxicity to predict drug safety.

Authors:  F Peter Guengerich; James S MacDonald
Journal:  Chem Res Toxicol       Date:  2007-02-16       Impact factor: 3.739

4.  Chloramphenicol oxamylethanolamine as an end product of chloramphenicol metabolism in rat and humans: evidence for the formation of a phospholipid adduct.

Authors:  J P Cravedi; E Perdu-Durand; M Baradat; J Alary; L Debrauwer; G Bories
Journal:  Chem Res Toxicol       Date:  1995 Jul-Aug       Impact factor: 3.739

5.  Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.

Authors:  John P O'Donnell; Deepak K Dalvie; Amit S Kalgutkar; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

Review 6.  Chloramphenicol: A review of its use in clinical practice.

Authors:  H M Feder; C Osier; E G Maderazo
Journal:  Rev Infect Dis       Date:  1981 May-Jun

7.  Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry.

Authors:  Timo Rousu; Olavi Pelkonen; Ari Tolonen
Journal:  Rapid Commun Mass Spectrom       Date:  2009-03       Impact factor: 2.419

Review 8.  Mechanisms of immune-mediated liver injury.

Authors:  David H Adams; Cynthia Ju; Shashi K Ramaiah; Jack Uetrecht; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2010-01-13       Impact factor: 4.849

9.  Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.

Authors:  D T Wong; F P Bymaster; L R Reid; D A Mayle; J H Krushinski; D W Robertson
Journal:  Neuropsychopharmacology       Date:  1993-06       Impact factor: 7.853

Review 10.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

View more
  6 in total

1.  Active Compounds in Zingiber officinale as Possible Redox Inhibitors of 5-Lipoxygenase Using an In Silico Approach.

Authors:  Jaqueline Stephanie Ley-Martínez; Jose Erick Ortega-Valencia; Oscar García-Barradas; Maribel Jiménez-Fernández; Esmeralda Uribe-Lam; Carlos Iván Vencedor-Meraz; Jacqueline Oliva-Ramírez
Journal:  Int J Mol Sci       Date:  2022-05-29       Impact factor: 6.208

2.  Site-Level Bioactivity of Small-Molecules from Deep-Learned Representations of Quantum Chemistry.

Authors:  Kathryn Sarullo; Matthew K Matlock; S Joshua Swamidass
Journal:  J Phys Chem A       Date:  2020-10-21       Impact factor: 2.781

3.  Modeling the Bioactivation and Subsequent Reactivity of Drugs.

Authors:  Tyler B Hughes; Noah Flynn; Na Le Dang; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2021-01-26       Impact factor: 3.739

4.  Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin.

Authors:  Dakota L Pouncey; Dustyn A Barnette; Riley W Sinnott; Sarah J Phillips; Noah R Flynn; Howard P Hendrickson; S Joshua Swamidass; Grover P Miller
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

5.  Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites.

Authors:  Tyler B Hughes; Na Le Dang; Ayush Kumar; Noah R Flynn; S Joshua Swamidass
Journal:  J Chem Inf Model       Date:  2020-09-16       Impact factor: 4.956

6.  XenoNet: Inference and Likelihood of Intermediate Metabolite Formation.

Authors:  Noah R Flynn; Na Le Dang; Michael D Ward; S Joshua Swamidass
Journal:  J Chem Inf Model       Date:  2020-06-29       Impact factor: 4.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.